Journal
BMC MEDICINE
Volume 13, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12916-015-0457-6
Keywords
Castration-resistant; Disease progression; Drug resistance; Prostatic neoplasms
Categories
Funding
- NIH [RO1 CA 165263 - 13]
- Stand Up To Cancer - Prostate Cancer Foundation - Prostate Dream Team Translational Cancer Research Grant [SU2C-AACR-PCF DT0812]
- Movember Foundation
- Medivation/Astellas
- [DOD PC111467]
Ask authors/readers for more resources
Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways leading to CRPC, including enzalutamide and abiraterone. While there is significant survival benefit, primary and secondary resistance to these therapies develops rapidly. Up to one-third of patients have primary resistance to enzalutamide and abiraterone; the remaining patients eventually progress on treatment. Understanding the mechanisms of resistance resulting in progression as well as identifying new targetable pathways remains the focus of current prostate cancer research. We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available